On August 30, 2021 ImmixBio reported to assess the safety, tolerability, and efficacy of IMX-110 in combination with tislelizumab in a P-I/IIa trial in patients with advanced solid tumors (Press release, Immix Biopharma, AUG 30, 2021, View Source [SID1234588074])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The novel approach of combining ImmixBio’s tissue specific therapeutics (TSTx) with immunotherapies could expand the population of cancer patients experiencing extended remissions
The pre-clinical studies showed IMX-110 turns "cold" tumors "hot," and IMX-110 + murine anti-PD-1 demonstrated extended survival in a genetic mouse model of pancreatic cancer vs multi-drug combinations in the literature showed substantial rationale to combine IMX-110 and tislelizumab